【概要】
心不全診断や循環動態をみる上でうっ血の評価は重要である。救急外来での急性心不全の迅速な診断や、心不全患者の入院では退院時・退院後を含め数多くのポイント/状況下で、うっ血の評価が行われる。このため、「より簡便・迅速・低コスト」なうっ血評価法の有用性は高い。
本ウェビナーでは、推定血漿量(ePV – ヘモグロビンとヘマトクリットの実測値から計算する簡便な式)を紹介。ePVが、簡便かつ低侵襲的で、現行の心負荷の指標を代替的に評価でき、心不全診断の一助となり、心不全予後と関連することを、演者自身による直近2018-22年のePV関連英文文献からのデータも含めて示される。
循環器内科のみならず麻酔科、心臓血管外科、救命救急、ICUのドクター、医療関係者の方々にご視聴頂きたいトピックです。
【2023年7月26日(水)18時より配信】（JST）
演者：小林 正武 先生(東京医科大学 医学部 循環器内科分野 助教)
Data: Quarta-feira, 11 Maio, 2022
Hora: 19:00 Brasilia Time
Um dos assuntos mais importantes, que vem sendo discutido ultimamente, no manejo de pacientes graves é como controlar o balanço de fluídos. A soma entre todos os volumes infundidos e retirados de um paciente tem impacto no manejo, no prognóstico e também na mortalidade. A variação do Volume Plasmático se mostra como uma ferramenta útil, barata e precisa nesse universo.
Teremos a oportunidade de conversar sobre os múltiplos aspectos desse parâmetro, como calculá-lo e como utilizá-lo no prognóstico. O acompanhamento do ePV possibilita melhor avaliação do paciente, bem como a modificação das condutas no momento adequado para alterar a história do paciente.
Venha participar com a gente desse novo webinar da Nova Biomedical!
Apresentador
Dr. Rubens Lodi
Nephrologist – Medical and Scientific Affairs Director
Nova Biomedical
New studies have reinforced the clinical importance of ePV as a diagnostic and prognostic tool in many clinical settings, particularly critical care. The ePV can be calculated using several formulas, mostly based on hemoglobin and hematocrit and sometimes body weight. It has been shown to provide useful prognostic information in patients with heart failure, myocardial infarction, renal failure, and recently acute respiratory distress syndrome (ARDS). Additionally, it has been associated with all-cause mortality and mortality from cancer in large cohort studies. This webinar will review the epidemiology, predictive power and potential clinical uses of ePV, especially in critically ill patients. We will discuss the origin of PV measurement, other techniques for PV measurement, and explore the pathophysiology of how PV can affect various disease processes, with special focus on ARDS and acute illnesses.
Measuring ePV in Critical Care
There is growing recognition that PV is an important parameter to determine in various disease processes. Nova Biomedical offers a blood gas analyzer that can calculate and trend ePV and ΔPV at the point-of-care as part of a comprehensive blood gas/critical care profile. Since ePV requires both measured hemoglobin and hematocrit, Nova’s blood gas analyzer is uniquely qualified to give an accurate calculation of ePV. This portion of the webinar will review this technology and reinforce the clinical importance of ePV as part of the blood gas critical care profile.
Thomas Metkus, MD
Divisions of Cardiology and Cardiac Surgery, Departments of Medicine and Surgery
Johns Hopkins University School of Medicine
Dennis Begos, MD, FACS, FACRS
Medical Director, Medical and Scientific Affairs
Nova Biomedical